Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
15.90
+1.87 (13.33%)
At close: Jan 22, 2026, 4:00 PM EST
15.79
-0.11 (-0.69%)
After-hours: Jan 22, 2026, 4:37 PM EST
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $13.78M in the quarter ending September 30, 2025, with 51.27% growth. This brings the company's revenue in the last twelve months to $57.53M, up 33.52% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+33.52%
P/S Ratio
25.57
Revenue / Employee
$142,749
Employees
403
Market Cap
1.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.76B |
| Novavax | 1.06B |
| Tango Therapeutics | 66.50M |
| Agios Pharmaceuticals | 44.79M |
| Precigen | 6.31M |
NTLA News
- 8 days ago - Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - The Short List — Top 10 Most Shorted Stocks Right Now - Benzinga
- 2 months ago - Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 2 months ago - Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 2 months ago - Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - US FDA places clinical hold on Intellia's two gene-editing treatment trials - Reuters